Video-on-demand service receives third round of funding from Cisco, AT&T, and Blueprint.
|
Investors send the RNAi company’s stock down on news of follow-on offering.
|
The CEO of Sirna Therapeutics discusses the first human trials of a drug candidate based on breakthrough RNAi technology.
|
Caris becomes the majority shareholder in Pathology Partners, investing $120 million to recapitalize it.
|